Enrique Conterno - FibroGen CEO Director
| FGEN Stock | MXN 7.94 0.89 12.62% |
Insider
Enrique Conterno is CEO Director of FibroGen
| Age | 56 |
| Phone | 415 978 1200 |
| Web | https://www.fibrogen.com |
FibroGen Management Efficiency
The company has return on total asset (ROA) of (0.2656) % which means that it has lost $0.2656 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.8478) %, meaning that it generated substantial loss on money invested by shareholders. FibroGen's management efficiency ratios could be used to measure how well FibroGen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Dawid Myburgh | Glencore plc | N/A | |
| Carmen Bozic | Vertex Pharmaceuticals | N/A | |
| Stuart BSc | Vertex Pharmaceuticals | 57 | |
| Gerald Bruce | Vertex Pharmaceuticals | N/A | |
| Nia Tatsis | Vertex Pharmaceuticals | N/A | |
| Damian Esq | Vertex Pharmaceuticals | 47 | |
| Michael Fahrbach | Glencore plc | N/A | |
| Giles Jones | Glencore plc | 55 | |
| Diana McKenzie | Vertex Pharmaceuticals | 54 | |
| Japie Fullard | Glencore plc | N/A | |
| Ourania Tatsis | Vertex Pharmaceuticals | 52 | |
| Susie Lisa | Vertex Pharmaceuticals | N/A | |
| Kristen Ambrose | Vertex Pharmaceuticals | 46 | |
| Mike Tirozzi | Vertex Pharmaceuticals | N/A | |
| Daniel Gelemovich | Controladora Vuela Compaa | N/A | |
| Guadalupe Margain | Controladora Vuela Compaa | 48 | |
| Peter Freyberg | Glencore plc | 64 | |
| Renato Salomone | Controladora Vuela Compaa | N/A | |
| MD FASN | Vertex Pharmaceuticals | 50 | |
| Shaun Teichner | Glencore plc | N/A | |
| Gary Nagle | Glencore plc | 48 | |
Management Performance
| Return On Equity | -1.85 | |||
| Return On Asset | -0.27 |
FibroGen Leadership Team
Elected by the shareholders, the FibroGen's board of directors comprises two types of representatives: FibroGen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of FibroGen. The board's role is to monitor FibroGen's management team and ensure that shareholders' interests are well served. FibroGen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, FibroGen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mr JD, Chief Officer | ||
| Enrique Conterno, CEO Director | ||
| Barry Berkowitz, Founder | ||
| Christine Chung, VP Operations | ||
| Elias Kouchakji, Drug Devel | ||
| Juan Graham, Chief Officer | ||
| Karen Bergman, VP Communications | ||
| Thane Wettig, Ex Officer | ||
| MPH MD, Ex Officer | ||
| John Hunter, Chief Officer |
FibroGen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is FibroGen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.85 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (2.94) % | |||
| Operating Margin | (2.52) % | |||
| Current Valuation | 21.87 B | |||
| Shares Outstanding | 93.96 M | |||
| Shares Owned By Insiders | 7.82 % | |||
| Shares Owned By Institutions | 78.80 % | |||
| Price To Book | 54.45 X | |||
| Price To Sales | 231.63 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for FibroGen Stock Analysis
When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.